Genmab A/S(GMAB)Earnings, Financials & Key Ratios
GMAB•NASDAQ
16.4× P/E·Price updated Jun 19, 2026
AboutGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Show more
- Revenue$3.72B-82.7%
- EBITDA$1.32B-81.4%
- Net Income$964M-87.7%
- EPS (Diluted)1.54-87.3%
- Gross Margin91.69%-3.9%
- EBITDA Margin35.51%+7.4%
- Operating Margin33.6%+7.9%
- Net Margin25.89%-29.0%
- ROE4.53%-80.3%
GMAB Key Insights
Genmab A/S (GMAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 30.9% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 3.0% through buybacks
- ✓Healthy 5Y average net margin of 32.3%
✗Weaknesses
- ✗Profits declining 27.3% over 5 years
- ✗Sales declining 18.1% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GMAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GMAB Price & Volume
Genmab A/S (GMAB) stock price & volume — 10-year historical chart
Loading chart...
GMAB Growth Metrics
Genmab A/S (GMAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.63%
5 Years-18.11%
3 Years-36.45%
TTM-34.41%
Profit CAGR
10 Years2.36%
5 Years-27.34%
3 Years-43.88%
TTM-52.54%
EPS CAGR
10 Years2.03%
5 Years-26.58%
3 Years-42.87%
TTM-59.7%
Return on Capital
10 Years20.83%
5 Years15.74%
3 Years13.51%
Last Year4.82%
GMAB Recent Earnings
Genmab A/S (GMAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.15+0.0%
$0.15
Rev
$896M-1.1%
$906M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.05-89.1%
$0.46
Rev
$1.1B-0.8%
$1.1B
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.65+35.4%
$0.48
Rev
$1.0B+1.1%
$1.0B
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.54+38.5%
$0.39
Rev
$925M-2.9%
$953M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.15vs $0.15+0.0% | $896Mvs $906M-1.1% |
| Q1 2026 | Feb 17, 2026 | $0.05vs $0.46-89.1% | $1.1Bvs $1.1B-0.8% |
| Q4 2025 | Nov 6, 2025 | $0.65vs $0.48+35.4% | $1.0Bvs $1.0B+1.1% |
| Q3 2025 | Aug 7, 2025 | $0.54vs $0.39+38.5% | $925Mvs $953M-2.9% |
Based on last 12 quarters of dataView full earnings history →
GMAB Peer Comparison
Genmab A/S (GMAB) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 |
Compare GMAB vs Peers
Genmab A/S (GMAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GMAB Income Statement
Genmab A/S (GMAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.37B | 3.03B | 5.37B | 10.11B | 8.42B | 14.51B | 16.47B | 21.53B | 3.72B | 8.84B |
Revenue Growth % | 30.25% | 27.89% | 77.38% | 88.43% | -16.75% | 72.33% | 13.57% | 30.67% | -82.7% | -34.41% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 226M | 985M | 309.24M | 565.21M |
COGS % of Revenue | - | - | - | - | - | - | 1.37% | 4.58% | 8.31% | - |
Gross Profit | 2.37B▲ 0% | 3.03B▲ 27.9% | 5.37B▲ 77.4% | 10.11B▲ 88.4% | 8.42B▼ 16.8% | 14.51B▲ 72.3% | 16.25B▲ 12.0% | 20.54B▲ 26.4% | 3.41B▼ 83.4% | 8.27B▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 98.63% | 95.42% | 91.69% | 93.6% |
Gross Profit Growth % | 30.25% | 27.89% | 77.38% | 88.43% | -16.75% | 72.33% | 12.02% | 26.42% | -83.38% | - |
Operating Expenses | 1.02B | 1.64B | 2.73B | 3.8B | 5.46B | 8.24B | 10.93B | 13.84B | 2.16B | 5.06B |
OpEx % of Revenue | 43.17% | 54.37% | 50.84% | 37.56% | 64.92% | 56.79% | 66.33% | 64.29% | 58.09% | - |
Selling, General & Admin | 146.99M | 213.69M | 342M | 661M | 1.28B | 2.68B | 3.3B | 3.79B | 602.47M | 1.43B |
SG&A % of Revenue | 6.21% | 7.06% | 6.37% | 6.54% | 15.24% | 18.45% | 20.01% | 17.61% | 16.18% | - |
Research & Development | 874.28M | 1.43B | 2.39B | 3.14B | 4.18B | 5.56B | 7.63B | 9.75B | 1.56B | 3.63B |
R&D % of Revenue | 36.96% | 47.31% | 44.47% | 31.03% | 49.67% | 38.35% | 46.32% | 45.28% | 41.91% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300M | 0 | 0 |
Operating Income | 1.34B▲ 0% | 1.38B▲ 2.7% | 2.64B▲ 91.1% | 6.31B▲ 139.3% | 2.95B▼ 53.2% | 6.27B▲ 112.2% | 5.32B▼ 15.1% | 6.7B▲ 26.0% | 1.25B▼ 81.3% | 3.21B▲ 0% |
Operating Margin % | 56.83% | 45.63% | 49.16% | 62.44% | 35.08% | 43.21% | 32.3% | 31.14% | 33.6% | 36.3% |
Operating Income Growth % | 27.67% | 2.69% | 91.12% | 139.31% | -53.22% | 112.22% | -15.09% | 25.97% | -81.34% | - |
EBITDA | 1.41B | 1.47B | 2.78B | 6.56B | 3.2B | 6.63B | 5.56B | 7.12B | 1.32B | 3.33B |
EBITDA Margin % | 59.78% | 48.53% | 51.75% | 64.87% | 38.05% | 45.7% | 33.76% | 33.06% | 35.51% | 37.65% |
EBITDA Growth % | 29.29% | 3.81% | 89.17% | 136.19% | -51.17% | 106.96% | -16.11% | 27.96% | -81.42% | -31.93% |
D&A (Non-Cash Add-back) | 70M | 87.7M | 139M | 246M | 250M | 362M | 240M | 413M | 71.06M | 119.39M |
EBIT | 1.42B | 1.61B | 2.87B | 5.91B | 3.93B | 6.97B | 5.71B | 9.28B | 1.25B | 3.69B |
Net Interest Income | 39M | 63M | 113M | 174M | 184M | 303M | 912M | 875M | 77.06M | 36.02M |
Interest Income | 41M | 62.92M | 120M | 184M | 197M | 324M | 939M | 995M | 138.11M | 252.33M |
Interest Expense | 2M | 417K | 7M | 10M | 13M | 21M | 27M | 120M | 61.05M | 216.31M |
Other Income/Expense | -280.45M | 231.69M | 221M | -409M | 965M | 678M | 316M | 2.46B | -46.04M | 83.24M |
Pretax Income | 1.06B▲ 0% | 1.61B▲ 51.5% | 2.86B▲ 77.4% | 5.9B▲ 106.5% | 3.92B▼ 33.6% | 6.95B▲ 77.3% | 5.64B▼ 18.8% | 9.16B▲ 62.6% | 1.2B▼ 86.9% | 3.29B▲ 0% |
Pretax Margin % | 44.97% | 53.29% | 53.28% | 58.39% | 46.55% | 47.88% | 34.22% | 42.57% | 32.37% | 37.25% |
Income Tax | -39.83M | 139.83M | 693M | 1.15B | 961M | 1.49B | 1.28B | 1.32B | 241.19M | 677.33M |
Effective Tax Rate % | -3.74% | 8.67% | 24.24% | 19.41% | 24.53% | 21.5% | 22.8% | 14.4% | 20.02% | 20.58% |
Net Income | 1.1B▲ 0% | 1.47B▲ 33.4% | 2.17B▲ 47.1% | 4.76B▲ 119.7% | 2.96B▼ 37.9% | 5.45B▲ 84.4% | 4.35B▼ 20.2% | 7.84B▲ 80.2% | 963.76M▼ 87.7% | 2.61B▲ 0% |
Net Margin % | 46.65% | 48.66% | 40.37% | 47.06% | 35.13% | 37.59% | 26.42% | 36.44% | 25.89% | 29.58% |
Net Income Growth % | -7.04% | 33.4% | 47.13% | 119.67% | -37.85% | 84.38% | -20.18% | 80.24% | -87.71% | -52.54% |
Net Income (Continuing) | 1.1B | 1.47B | 2.17B | 4.76B | 2.96B | 5.45B | 4.35B | 7.84B | 963.76M | 2.61B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.78▲ 0% | 2.37▲ 33.1% | 3.40▲ 43.5% | 7.22▲ 112.4% | 4.48▼ 38.0% | 8.26▲ 84.4% | 6.60▼ 20.1% | 12.14▲ 83.9% | 1.54▼ 87.3% | 4.09▲ 0% |
EPS Growth % | -7.29% | 33.15% | 43.46% | 112.35% | -37.95% | 84.38% | -20.1% | 83.94% | -87.31% | -59.7% |
EPS (Basic) | 1.81 | 2.40 | 3.44 | 7.30 | 4.52 | 8.34 | 6.60 | 12.14 | 1.55 | - |
Diluted Shares Outstanding | 620.94M | 620.45M | 636.37M | 658.86M | 660.46M | 660.1M | 659.15M | 646.33M | 626.92M | 638.55M |
Basic Shares Outstanding | 608.34M | 612.68M | 629.63M | 651.79M | 653.96M | 653.87M | 659.19M | 646.34M | 621.51M | 613.84M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GMAB Balance Sheet
Genmab A/S (GMAB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.06B | 7.43B | 13.96B | 18.79B | 22.74B | 28.22B | 33.14B | 27.85B | 2.88B | 2.57B |
Cash & Short-Term Investments | 5.42B | 6.11B | 10.97B | 16.08B | 19.34B | 22.32B | 28.14B | 21.1B | 1.71B | 1.52B |
Cash Only | 1.35B | 532.91M | 3.55B | 7.26B | 8.96B | 9.89B | 14.87B | 9.86B | 1.71B | 1.52B |
Short-Term Investments | 4.08B | 5.57B | 7.42B | 8.82B | 10.38B | 12.43B | 13.27B | 11.24B | 0 | 0 |
Accounts Receivable | 579M | 1.33B | 2.99B | 2.46B | 3.37B | 5.71B | 4.95B | 6.69B | 1.15B | 1.03B |
Days Sales Outstanding | 89.34 | 160.11 | 203.38 | 88.91 | 146.01 | 143.74 | 109.61 | 113.45 | 112.69 | 98.61 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 57M | 62M | 17.96M | 21M |
Days Inventory Outstanding | - | - | - | - | - | - | 92.06 | 22.97 | 21.2 | 21.85 |
Other Current Assets | 0 | 0 | 0 | 249M | 31M | 182M | 0 | 0 | 3 | 0 |
Total Non-Current Assets | 543.51M | 1.03B | 1.18B | 2.35B | 1.89B | 1.9B | 2.15B | 17.96B | 9.97B | 9.8B |
Property, Plant & Equipment | 113.42M | 161.54M | 414M | 736M | 975M | 1.32B | 1.64B | 263.83M | 279.36M | 265M |
Fixed Asset Turnover | 20.86x | 18.73x | 12.96x | 13.74x | 8.63x | 10.97x | 10.04x | 81.59x | 13.33x | 13.78x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.54B | 354.19M | 354.99M |
Intangible Assets | 124.39M | 470.36M | 470M | 338M | 254M | 146M | 101M | 12.34B | 9.1B | 8.95B |
Long-Term Investments | 8.76M | 9.62M | 149M | 1.08B | 371M | 133M | 134M | 228M | 58.87M | 378.66M |
Other Non-Current Assets | 0 | 0 | 11M | 197M | 291M | 300M | 62M | 2.46B | 4 | 0 |
Total Assets | 6.6B▲ 0% | 8.46B▲ 28.1% | 15.14B▲ 79.0% | 21.14B▲ 39.6% | 24.63B▲ 16.5% | 30.12B▲ 22.3% | 35.29B▲ 17.2% | 45.81B▲ 29.8% | 12.84B▼ 72.0% | 12.38B▲ 0% |
Asset Turnover | 0.36x | 0.36x | 0.35x | 0.48x | 0.34x | 0.48x | 0.47x | 0.47x | 0.29x | 0.48x |
Asset Growth % | 26.05% | 28.14% | 78.99% | 39.61% | 16.48% | 22.3% | 17.17% | 29.82% | -71.96% | -217.98% |
Total Current Liabilities | 327.12M | 443.35M | 938M | 1.25B | 1.57B | 1.82B | 2.48B | 5.31B | 1.42B | 1.18B |
Accounts Payable | 579M | 1.33B | 0 | 0 | 350M | 0 | 0 | 0 | 1.07B | 860.99M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | 1.26K | 311.19 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 273M | 293M |
Deferred Revenue (Current) | 150.65M | 0 | 0 | 0 | 0 | 0 | 33M | 24M | 23.95M | 88.97M |
Other Current Liabilities | 0 | -651K | 0 | 1.21B | 860M | 1.75B | 0 | 0 | -663.92K | 0 |
Current Ratio | 18.52x | 16.77x | 14.88x | 15.00x | 14.50x | 15.48x | 13.34x | 5.25x | 2.02x | 2.18x |
Quick Ratio | 18.52x | 16.77x | 14.88x | 15.00x | 14.50x | 15.48x | 13.32x | 5.24x | 2.01x | 2.17x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -1.12K | -190.73 |
Total Non-Current Liabilities | 3.63M | 3.29M | 158M | 769M | 863M | 1.01B | 1.2B | 3.81B | 5.59B | 5.52B |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5B | 4.93B |
Capital Lease Obligations | 0 | 0 | 155M | 277M | 363M | 523M | 680M | 937M | 133.69M | 1.22B |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.36B | 363.17M | 3.15B |
Other Non-Current Liabilities | 3.63M | 3.29M | 3M | 492M | 500M | 491M | 35M | 30M | 5M | 5M |
Total Liabilities | 330.75M | 446.64M | 1.1B | 2.02B | 2.43B | 2.84B | 3.68B | 9.11B | 7.01B | 6.69B |
Total Debt | 0 | 0 | 181M | 319M | 425M | 597M | 770M | 1.03B | 5.43B | 5.35B |
Net Debt | -1.35B | -532.91M | -3.37B | -6.94B | -8.53B | -9.3B | -14.1B | -8.83B | 3.71B | 3.83B |
Debt / Equity | - | - | 0.01x | 0.02x | 0.02x | 0.02x | 0.02x | 0.03x | 0.93x | 0.94x |
Debt / EBITDA | - | - | 0.07x | 0.05x | 0.13x | 0.09x | 0.14x | 0.14x | 4.10x | 1.61x |
Net Debt / EBITDA | -0.95x | -0.36x | -1.21x | -1.06x | -2.66x | -1.40x | -2.53x | -1.24x | 2.81x | 1.15x |
Interest Coverage | 709.00x | 3865.71x | 409.43x | 591.40x | 302.38x | 331.71x | 211.37x | 77.37x | 20.49x | 17.06x |
Total Equity | 6.27B▲ 0% | 8.01B▲ 27.8% | 14.05B▲ 75.3% | 19.12B▲ 36.1% | 22.2B▲ 16.1% | 27.28B▲ 22.9% | 31.61B▲ 15.9% | 36.7B▲ 16.1% | 5.83B▼ 84.1% | 5.68B▲ 0% |
Equity Growth % | 29.95% | 27.78% | 75.29% | 36.11% | 16.08% | 22.91% | 15.86% | 16.09% | -84.1% | -240.68% |
Book Value per Share | 10.10 | 12.92 | 22.08 | 29.02 | 33.61 | 41.33 | 47.96 | 56.78 | 9.31 | 8.90 |
Total Shareholders' Equity | 6.27B | 8.01B | 14.05B | 19.12B | 22.2B | 27.28B | 31.61B | 36.7B | 5.83B | 5.68B |
Common Stock | 61.19M | 61.5M | 65M | 66M | 66M | 66M | 66M | 66M | 9.98M | 10M |
Retained Earnings | -1.85B | -197.46M | 2.13B | 7.11B | 10.02B | 14.81B | 19.02B | 23.55B | 4.09B | 4.09B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 82.08M | 91.71M | 98M | 54M | 81M | 98M | 60M | 490M | -180.59M | -339.99M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GMAB Cash Flow Statement
Genmab A/S (GMAB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.59B | 1.01B | 1.33B | 6.43B | 2.23B | 3.91B | 7.38B | 7.77B | 1.19B | 1.23B |
Operating CF Margin % | 67.17% | 33.55% | 24.71% | 63.62% | 26.47% | 26.97% | 44.8% | 36.1% | 31.88% | - |
Operating CF Growth % | 384.86% | -36.14% | 30.67% | 385.14% | -65.37% | 75.58% | 88.65% | 5.3% | -84.73% | -102.07% |
Net Income | 1.06B | 1.61B | 2.86B | 4.76B | 3.98B | 7.04B | 5.64B | 7.84B | 963.76M | 2.61B |
Depreciation & Amortization | 69.75M | 87.6M | 139M | 266M | 248M | 362M | 295M | 413M | 71.06M | 119.39M |
Stock-Based Compensation | 75.98M | 90.76M | 147M | 200M | 310M | 439M | 586M | 721M | 0 | 243.12M |
Deferred Taxes | -140.58M | 90.52M | -385M | 0 | -546M | 0 | 122M | 0 | 0 | 0 |
Other Non-Cash Items | 280.45M | -231.69M | -216M | 903M | -997M | -1.99B | -622M | 388M | -73.06M | -1.85B |
Working Capital Changes | 239.65M | -634.37M | -1.22B | 306M | -770M | -1.93B | 1.36B | -1.59B | 225.18M | -523.58M |
Change in Receivables | 270.35M | -768.15M | -1.66B | 306M | -1.07B | -2.12B | 797M | -1.59B | -166.13M | -1.2B |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -57M | -5M | -9.01M | -14.35M |
Change in Payables | 0 | 133.78M | 440M | 0 | 304M | 283M | 622M | 0 | 400.32M | 37.17M |
Cash from Investing | -667.57M | -1.78B | -1.98B | -2.35B | -961M | -2.76B | -1.28B | -9.91B | -5.65B | -5.47B |
Capital Expenditures | -88.51M | -477.37M | -111M | -307M | -252M | -317M | -366M | -187M | -55.04M | -83.36M |
CapEx % of Revenue | 3.74% | 15.78% | 2.07% | 3.04% | 2.99% | 2.19% | 2.22% | 0.87% | 1.48% | 0.94% |
Acquisitions | 0 | 405.67M | 32M | 0 | 709M | 2.44B | 0 | -12.25B | -7.22B | -7.22B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -579.06M | -405.67M | -32M | -2.04B | -709M | -2.44B | -10M | -117M | 0 | 0 |
Cash from Financing | 214.91M | -70.9M | 3.66B | 71M | -420M | -789M | -606M | -3.92B | 4.79B | 2.46B |
Debt Issued (Net) | 0 | 0 | -31M | -44M | -58M | -73M | -91M | -60M | 5.23B | -93.9M |
Equity Issued (Net) | 0 | -146M | 3.87B | -25M | -447M | -908M | -564M | -3.99B | -407.32M | -2.68B |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -146M | 0 | -25M | -447M | -908M | -564M | -3.99B | -430.34M | -2.69B |
Other Financing | 214.91M | 75.1M | -182M | 140M | 85M | 192M | 49M | 129M | -31.02M | 5.24B |
Net Change in Cash | 1.04B▲ 0% | -814.64M▼ 178.3% | 3.02B▲ 470.6% | 3.71B▲ 22.8% | 1.7B▼ 54.2% | 936M▼ 44.8% | 4.97B▲ 431.4% | -5.01B▼ 200.7% | 345.33M▲ 106.9% | -1.82B▲ 0% |
Free Cash Flow | 1.5B▲ 0% | 537.42M▼ 64.2% | 1.22B▲ 126.1% | 6.13B▲ 404.2% | 1.98B▼ 67.7% | 3.6B▲ 81.9% | 7B▲ 94.8% | 7.58B▲ 8.3% | 1.15B▼ 84.8% | 1.15B▲ 0% |
FCF Margin % | 63.43% | 17.77% | 22.64% | 60.59% | 23.48% | 24.78% | 42.52% | 35.23% | 30.89% | 13% |
FCF Growth % | 409.3% | -64.18% | 126.08% | 404.2% | -67.74% | 81.93% | 94.83% | 8.28% | -84.84% | -72.94% |
FCF per Share | 2.42 | 0.87 | 1.91 | 9.30 | 2.99 | 5.45 | 10.63 | 11.73 | 1.83 | 1.80 |
FCF Conversion (FCF/Net Income) | 1.44x | 0.69x | 0.61x | 1.35x | 0.75x | 0.72x | 1.70x | 0.99x | 1.23x | 0.44x |
Interest Paid | 0 | 0 | 0 | 20M | 0 | 0 | 0 | 35M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GMAB Key Ratios
Genmab A/S (GMAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 19.89% | 20.61% | 19.64% | 28.69% | 14.31% | 22.04% | 14.78% | 22.97% | 4.53% | 20.56% |
Return on Invested Capital (ROIC) | 21.35% | 16.69% | 21.79% | 41.43% | 17.14% | 29.7% | 22.48% | 22.16% | 5.02% | 19.44% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 98.63% | 95.42% | 91.69% | 93.6% |
Net Margin | 46.65% | 48.66% | 40.37% | 47.06% | 35.13% | 37.59% | 26.42% | 36.44% | 25.89% | 29.58% |
Debt / Equity | - | - | 0.01x | 0.02x | 0.02x | 0.02x | 0.02x | 0.03x | 0.93x | 0.94x |
Interest Coverage | 709.00x | 3865.71x | 409.43x | 591.40x | 302.38x | 331.71x | 211.37x | 77.37x | 20.49x | 17.06x |
FCF Conversion | 1.44x | 0.69x | 0.61x | 1.35x | 0.75x | 0.72x | 1.70x | 0.99x | 1.23x | 0.44x |
Revenue Growth | 30.25% | 27.89% | 77.38% | 88.43% | -16.75% | 72.33% | 13.57% | 30.67% | -82.7% | -34.41% |
Related:GMAB Dividend History·GMAB Revenue History·GMAB Price History·GMAB P/E History·GMAB Financial Ratios·GMAB Institutional Holders
GMAB Frequently Asked Questions
Genmab A/S (GMAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Genmab A/S (GMAB) reported $8.84B in revenue for fiscal year 2025.
Genmab A/S (GMAB) saw revenue decline by 82.7% over the past year.
Yes, Genmab A/S (GMAB) is profitable, generating $2.61B in net income for fiscal year 2025 (25.9% net margin).
Dividend & Returns
Genmab A/S (GMAB) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
Genmab A/S (GMAB) generated $1.15B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.